SURVYR

BEAM

Beam Therapeutics Inc.
$24.90
+$1.11 (4.67%)Oct 27 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-24%-7%+9%+26%+43%Oct 2025Oct 2026Apr 202652w high $38.2652w low $20.23
BEAMSPY
Wall St. Highest PT $80.00 (+221.3%) Wall St. Avg PT $52.15 (+109.5%)
$21$39$58$76$95POC $27Hi $80Avg $52
Underwater Drawdown %Max DD -39.1%Current -34.3%
0.0%-39.1%
Relative Strength vs SPY-20.4% vs SPYUnderperforming
+37%0%-37%
1W
−$0.03 (0.12%)
1M
+$0.63 (2.60%)
3M
−$1.39 (5.29%)
6M
−$5.66 (18.52%)
YTD
−$2.82 (10.17%)
1Y
−$1.83 (6.85%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
15 analysts · mean score 1.33
1 = Strong Buy · 5 = Sell
Strong Buy1280%
Buy17%
Hold213%
Underperform00%
Sell00%
Wall Street consensus · as of Oct 22, 2026
Analyst price targets
Current price$24.90
Average target$52.15
+$27.25 (+109.5%) upsideaverage target vs current price
CurrentAverageMedian
Low$26.00
Median$45.00
High$80.00
12-month Wall Street target range · as of Oct 22, 2026

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$2.6B
P/E (next 12 months, estimated)-5.2
52-week range$20.23 – $38.26
Revenue growth (latest quarter vs a year ago)-94.2%
Dividend yieldNo dividend
Analyst consensusStrong Buy (13)
Average analyst price target$52.15 (+109%)

What they do

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for BEAM yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Held by 1 of 7 live models: SURVYR. Long Book.

SURVYR. Long Book
2.5% of the book · Higher-risk sleeve
 HeldQuality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
Why it's in the SURVYR. Long Book

Picked for this research portfolio at the Oct 21, 2026 close (Higher-risk group, Biotech & health).

What would knock it out: Weights are fixed and there is no rebalance rule. Any change would be dated and shown here.

Earnings & events

BEAM earningsNext report in 6 days
Next report · quarter Sep 2026
Tue Nov 3, 2026Before the open
EPS consensus-$1.17
Revenue consensus–
Last 4 quarters · EPS vs estimate
Aug 4, 2026-$1.18est -$1.13−4.8%Below estimates
May 7, 2026-$0.91est -$1.01+10.1%Above estimates
Feb 24, 2026$2.33est -$1.12+309.0%Above estimates
Nov 4, 2025-$1.10est -$1.01−8.9%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-27 17:57:55 ET
24-1125-0225-0525-0825-1126-0226-0526-08-1.242.33
EstimateActual (beat)Actual (miss)

News & catalysts

More news
No recent headlines.
Insider trades
Evans John M.
Director, CEO · 2026-10-16
Sell
$599.6K
Evans John M.
Director, CEO · 2026-10-15
Sell
$589.1K
Cavanagh Bethany J
SVP, Finance and Treasurer · 2026-10-01
Sell
$4.6K
Simon Amy
Chief Medical Officer · 2026-07-27
Sell
$429.0K
None
None · None
Sell
–

Stats refreshed 2026-10-27 17:57:55 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026